Tech Company Potbotics Just Created a Revolutionary Strain-Recommending Gadget

Co-founder of Potbotics, David Goldstein, poses with one of his creations. Photo by Buck Ennis.

[dropcap class=”kp-dropcap”]P[/dropcap]otBotics is a high-tech startup founded by the father and son duo, David and Baruch Goldstein. While still in the company’s earl stages, the Goldsteins have managed to come up with a virtual budtender, as well as software that uses DNA and EEG scans to choose the most effective strain for your physiological make up. Potbotics is promoting PotBot, BrainBot, and NanoPot, all of which are gadgets that identify which strain to use based on each a patient’s own physiology. David Goldstein’s father Baruch previously worked on cognition tests for Alzheimer’s patients using EEG scans. The family is taking that technology to the world of cannabis. The Goldsteins want to prove that there is an even better – and scientifically sound way – of choosing cannabis based on more than today’s focus on strain name color, and smell.

PotBot is a virtual budtender. It’s a cloud-based, HIPAA-compliant cannabis recommendation engine kiosk that will suggest strains based on cutting-edge custom data such as neural-net algorithms and CBD levels.

BrainBot is software designed for a wireless EEG helmet (electroencephalogram) with an FDA-approved disposable cap that measures brain waves and identifies a patient’s neural response to cannabinoids. The patient breathes in a precisely measured, aerosolized cannabinoid mixture and the EEG will detect what areas in the brain are affected. “A lot of drug companies use EEG to validate performance,” David Goldstein told the Village Voice.

The NanoPot is a DNA reader for cannabis seeds. It will scan cannabis seeds using MIT-developed gene radar technology to better understand a strain’s molecular biology.

There are at least 750 cannabis strains with 300-350 that are genetically unique. Goldstein recently explained to Fortune,“No doctor is ever going to recommend Alpha OG Kush to a patient. They’re not going to use that terminology, but if they said, ‘Look for a strain with a higher CBD value with this kind of range of CBN,’ now we’re talking something that’s a little bit more digestible and acceptable in the medical community.”